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Summary The 'unopposed oestrogen hypothesis' for endometrial cancer maintains that risk is increased by
exposure to endogenous or exogenous oestrogen that is not opposed simultaneously by a progestagen, and
that this increased risk is due to the induced mitotic activity of the endometrial cells. Investigation of the
mitotic rate during the menstrual cycle shows that increases in plasma oestrogen concentration above the
relatively low levels of the early follicular phase do not produce any further increase in the mitotic rate of
endometrial cells. A modification of the unopposed oestrogen hypothesis which includes this upper limit in
the response of endometrial cells to oestrogen is consistent with the known dose-effect relationships between
endometrial cancer risk and both oestrogen replacement therapy and postmenopausal obesity; it also suggests
that the mechanism by which obesity increases risk in premenopausal women involves progesterone deficiency
rather than oestrogen excess, and that the protective effect of cigarette smoking may be greater in
postmenopausal than in premenopausal women.
Detailed analysis of the age-incidence curve for endometrial cancer in the light of this hypothesis suggests
that there will be lifelong effects of even short duration use of exogenous hormones. In particular, 5 years of
combination-type oral contraceptive use is likely to reduce a woman's lifetime risk of endometrial cancer by
some 60%; whereas 5 years of unopposed oestrogen replacement therapy is likely to increase her subsequent
lifetime risk by at least 90%; and even 5 years of 'adequately' opposed therapy is likely to increase subsequent
lifetime risk by at least 50%.
Epidemiological studies have shown that the risk of
developing endometrial cancer increases markedly with
increasing weight and with use of oestrogen replacement
therapy (ERT) or sequential-type oral contraceptives, and
decreases markedly with use of combination-type oral
contraceptives (COCs) (Weiss et al., 1980; Henderson et al.,
1983). These risk factors can all be explained in terms of the
'unopposed oestrogen hypothesis' for endometrial cancer
(Siiteri, 1978; Henderson et al., 1982).
In essence the unopposed oestrogen hypothesis maintains
that endometrial cancer risk is increased by exposure to endo-
genous or exogenous oestrogen which is not opposed by pro-
gesterone or a synthetic progestagen, and that this increased
risk is caused by the increased mitotic activity of the
endometrium induced by such exposure. It has, however, not
been clear that this hypothesis can explain the high relative
risk associated with obesity in premenopausal women.
In this paper we first argue, on the basis of studies of
premenopausal hormone levels and of endometrial mitotic
rates, that endometrial cell division is not increased by
increases in plasma oestrogen concentration above early
follicular levels. We show that epidemiological studies of the
effects of different doses of ERT on endometrial cancer risk
are consistent with the existence of such an upper limit, as
are studies of the effects of obesity on risk in postmeno-
pausal women. We then show how the existence of this
upper limit to effective oestrogen action suggests that
cigarette smoking has a different effect on endometrial
cancer risk in pre- and postmenopausal women. We also
explain why this upper limit suggests that the reason for the
increased risk of endometrial cancer in obese premenopausal
women is progesterone deficiency, not increased plasma
oestrogen concentration.
Finally we show that analysis of the age-incidence curve of
endometrial cancer in the context of the unopposed
oestrogen hypothesis implies that ERT plus progestagen for
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even 14 days per month [hormone replacement therapy
(HRT)] will still be associated with a significantly increased
risk of endometrial cancer, and that hormonal factors
affecting cell-division rates will have lifelong effects on
endometrial cancer risk. In particular we predict that use of
COCs by young women will provide them with significant
lifelong protection against endometrial cancer, and that even
relatively short-term use of both ERT and HRT will cause a
lifelong increase in endometrial cancer risk.
Oestrogens, progestagens and endometrial mitotic rate
Oestrogens stimulate mitosis in endometrial cells. Oestradiol
(E2) is the predominant intracellular oestrogen in the endo-
metrium [see Whitehead et al. (1981) for references], and in
this paper we limit our consideration of oestrogens to E2.
Progestagens dramatically reduce mitotic activity, mainly by
reducing the concentration of oestrogen receptors, and to a
lesser extent by increasing the metabolism of E2 to the less
active oestrone (El) and by stimulating differentiation of
endometrial cells to a secretory state [see Henderson et al.
(1982) for references].
Figure la shows the mitotic rate of the glandular
endometrial cells (Ferenczy et al., 1979) and figure lb the
fluctuating plasma concentrations of E2 and progesterone
(Thorneycroft et al., 1971; Goebelsmann & Mishell, 1979)
during the menstrual cycle. The two most important points
to note from Figure 1 are:
(1) The mitotic rate rises rapidly from a very low level
during menses to reach a near maximal level early on in the
cycle, probably by day 5, and then stays roughly constant
for 14 days until day 19, after which it drops again to a very
low level in the face of the post-ovulation increase in
progesterone.
(2) The maximal endometrial mitotic rate is induced by
the basal early follicular plasma E2 concentration; later
increases in E2 levels to not induce any further increase in
the mitotic rate. There thus appears to be an 'effective upper
limit' to the plasma concentration of E2: this upper limit is
no greater than 50pgml-1.
Very low E2 concentrations (5pgml1 or less) in slender
postmenopausal women are associated with an atrophic
Br. J. Cancer (1988), 57, 205-212 C The Macmillan Press Ltd., 1988206 T.J.A. KEY & M.C. PIKE
a
4 7
3-
x
.a)
C)
.0
-J
0-
3 5 7 9 11
Day of cycle
b
400 -
300
200
100
I
, -0:
I I III
I I I
1 3 5 7 9 1 1 13 15 17 19 21 23 25 27
Day of cycle
Figure 1 (a) Endometrial mitotic rate by day of cycle (day 1 is first day of menses and 28-day cycle assumed with ovulation on
day 14); (b) Serum concentrations of oestradiol and progesterone by day of cycle.
endometrium (very little mitotic activity), but there is little
information available about the nature of the dose-effect
relationship between unopposed E2 concentration and
mitotic rate between such low concentrations and the upper
limit.
The existence of the upper limit has important
implications. In particular the limit implies that in pre-
menopausal women changes in E2 will have little effect:
increases in E2 above 'normal' will not increase endometrial
cell division, and decreases in E2 will, at most, only decrease
mitotic activity for the few days of the cycle during which E2
is normally close to the basal 50 pgml-1 level. In postmeno-
pausal women, however, E2 is in the range of 5-20 pgml-1,
well below the upper limit. Increases in E2 will therefore
increase the endometrial mitotic rate until the upper limit for
E2 is reached, and decreases in E2 will decrease the mitotic
rate until the (unknown) lower limit for E2 is reached.
Oestradiol binding
Plasma E2 is mostly bound to protein: about half is bound
with high affinity to sex hormone binding globulin (SHBG)
and about half to albumin, with only - 2% being non-
protein bound or 'free' (Anderson, 1974). It is generally
accepted that the non-protein bound E2 is free to reach
intracellular receptors, and there is now increasingly per-
suasive evidence that the E2 bound to albumin may also be
'bioavailable' (Pardridge, 1986). In discussing the likely
effects of changes in E2 concentration it is therefore
necessary on occasion to consider parallel changes in the
protein binding of E2, which are largely determined by
changes in SHBG concentration. To estimate % non-protein
bound E2 and % non-SHBG bound E2 from knowledge of
total E2 and SHBG we have used the regression equations
given by Moore et al. (1983).
Oestrogen replacement therapy dose
Almost all studies of the relationship between ERT and
endometrial cancer risk have been effectively restricted to the
study of conjugated equine oestrogens (CEE, Premarin).
Table I shows the results of seven studies which have
considered the effect of the daily dose of CEE. All except
one (Kelsey et al., 1982) found that the risk was greater for
doses of 1.25 mgday- 1 (and above) than for doses of
0.625mgday-1 (and below), although in two studies this
trend was not adjusted for duration of use. Table II shows
the effect of the two doses, 0.625 mg and 1.25 mg, of CEE on
plasma E2, SHBG and estimated E2 binding. Although the
lower dose of CEE produces a plasma E2 concentration
approximately at the level of the 50pgml-1 upper limit, the
accompanying increase in SHBG results in non-protein
bound and non-SHBG bound E2 concentrations less than
those of the upper limit.
The existence of a dose-effect relationship between
endometrial cancer risk and CEE doses of 0.625mgday-1
and 1.25mgday-1 is therefore consistent with the postulated
upper limit for effective oestrogen. (Note: plasma E2
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Table I Oestrogen replacement therapy dose and risk ofendometrial cancera
Cases Controls ERT
Reference N Source N Source Doseb RRC Comments
Mack et al. 50 Population 217 Population .0.625 5.0 Apparent in each
(1976) >0.625 9.4 duration of use
category except the
shortest.
McDonald et al. 145 Hospital 580 Hospital <0.625 1.4 Not adjusted for
(1977) > 1.25 7.2 duration of use.
Weiss et al. 309 Population 272 Population <1.25 6.5 Not confounded by
(1979) > 1.25 7.6 duration of use.
Antunes et al. 330 Hospital 406 Hospital .0.625 3.5 Not adjusted for
(1979) . 1.25 6.1 duration of use.
Hulka et al. 173 Hospital 217 Population .0.625 1.7 for <3.5 yrs
(1980) 2.7 for . 3.5 yrs
>0.625 0.6 for <3.5 yrs
3.2 for >3.5 yrs
Kelsey et al. 148 Hospital 733 Hospital No dose effect after
(1982) adjusting for
duration of use.
Buring et al. 177 Hospital 396 Hospital <0.625 2.7 Highest RR with
(1986) . 1.25 3.8 high dose for long
duration.
aAbbreviations: ERT =oestrogen replacement therapy; RR =relative risk; bDose in mgday-1 of conjugated equine
oestrogens; cIn all studies controls are age matched or RRs are adjusted for age.
Table II Effect of two doses of conjugated equine oestrogens on
plasma E2, SHBG, non-protein bound E2 and non-SHBG bound
E2a
Non- Non-
Dose of protein SHBG
conjugated equine E2, SHBG, bound E2, bound E2,
oestrogens, mgday-1 pgml-1 nmoll- pgml-1 pgml-
None [premenopausal] 50b 60d 0.9e 34e
0.625 [postmenopausal] 50c 130d 0.7e 24e
1.25 [postmenopausal] 75C 180d 0.9e 26e
aAbbreviations: E2 =oestradiol; SHBG =sex hormone binding
globulin; bFrom Figure 1; cFrom Whitehead (1978); dFrom Geola et
al. (1980); eEstimated from mean E2 and SHBG concentrations,
using the regression equations given by Moore et al. (1983).
concentration after CEE is not strictly comparable to an
endogenous E2 concentration since it depends on the time
since the CEE was taken. The concentrations quoted here
are however likely to be near peak levels, 1 to 6.5 hours after
CEE ingestion, so the argument appears to be valid.)
Obesity and risk in postmenopausal women
Obesity is a well-established important risk factor for
endometrial cancer in postmenopausal women.
Obesity leads to increased peripheral production of El
from androstenedione (Siiteri & MacDonald, 1973), and
plasma concentrations of both El and E2 are positively
correlated with body weight in postmenopausal women
(Judd et al., 1976). Obesity is also strongly associated with a
decrease in SHBG concentration (Anderson, 1974) and thus
with an increase in the proportions of non-protein bound
and of non-SHBG bound E2. This increase in total E2, and
more specifically in bioavailable E2, is commonly considered
to be the cause of the increased endometrial cancer risk of
obese postmenopausal women (Siiteri, 1978).
Table III shows the relative risks associated with varying
degrees of obesity found in four studies. Risk increases
steadily with increasing weight. There is no suggestion that
there is an upper limit of obesity beyond which risk does not
increase further: for this result to be directly compatible with
the postulated upper limit to effective oestrogen concen-
tration, even severe obesity should not be associated with a
plasma E2 concentration (or bioavailable E2 concentration)
which exceeds the 50pgml-1 limit. Table IV shows the
estimated E2 levels with a body weight of approximately
110kg (200% 'ideal' weight). We note that, even at this
extreme weight, total, non-SHBG bound and non-protein
bound E2 values are below those of premenopausal women
in the early follicular phase. The steady increase in relative
risk, even into the highest weight category, is therefore
consistent with the postulated upper limit for effective
oestrogen concentration.
Smoking
Recent case-control studies have established that cigarette
smoking significantly reduces the risk of endometrial cancer
(Table V). The reduction in risk appears to be directly
related to the number of cigarettes smoked, and Baron
(1984) proposed that this was due to an anti-oestrogenic
effect of smoking. Two studies, including that with the
largest number of premenopausal women (Tyler et al., 1985)
found that the protective effect of smoking was confined to
postmenopausal women, but two smaller recent studies
found a protective effect in both premenopausal and post-
menopausal women.
A few studies have investigated oestrogen metabolism in
smokers. MacMahon et al. (1982) reported that pre-
menopausal luteal phase urinary excretion rates of El, E2
and oestriol (E3) were each reduced in smokers by -30%.
They found no changes in the follicular phase, and therefore
suggested that the observed lower luteal phase oestrogen
excretion of smokers was due to reduced ovarian production
rather than changes in liver metabolism. Michnovicz et al.
(1986), however, found that smokers had lower follicular
phase urinary excretion of El and E3 than non-smokers (by
47% and 66% respectively): they explained these changes208 T.J.A. KEY & M.C. PIKE
Table III Obesity and risk of endometrial cancer in postmenopausal womena
Cases Controls Obesity
Weight
Reference N Source N Source (kg) RRb Comments
Elwood et al. 200 Hospital 992 Population <58.2c 1.0 Adjusted for
(1977) 58.2- 1.0 parity,
66.1- 1.2 age at
74.0+ 1.9 menopause.
Kelsey et al. 164 Hospital 893 Hospital <57.0 1.0
(1982) 57.0- 1.3
66.0- 1.3
75.0+ 2.3
LaVecchia et al. 222 Hospital 471 Hospital <52.9c 1.0
(1984) 52.9- 1.6
66.1- 3.3
79.3+ 7.6
Lawrence et al. 42 Hospital 52 Population <68.0 1.0 Non-smokers,
(1987) 68.0- 2.5 non-ERT users.
81.6+ 11.6
aAbbreviations: ERT=oestrogen replacement therapy; RR=relative risk; bIn all studies controls are age
matched or RRs are adjusted for age. Elwood et al. (1977) study is age group 40-89, Kelsey et al. (1982) of
45-74, others are of postmenopausal women; cWeight estimated from Quetelet's Index (kgm-2) using a
standard height of 1.626m.
Table IV Estimates of E2, SHBG, non-protein bound E2 and non-
SHBG bound E2 in postmenopausal women of different weightsa
Non-protein Non-SHBG
Weight, E2, SHBG, bound E2, bound E2,
kg pgml-1 nmol1-I pgml-1 pgml-1
54.4b 11 50 0.2c 8c
108.8 25 27 0.5c 19C
aAbbreviations: E2 =oestradiol; SHBG =sex hormone binding
globulin. Data from Davidson et al. (1981) unless otherwise noted;
bApproximate body weight of a woman of neight 1.626m and ideal
body weight; cEstimated from mean E2 and SHBG concentrations,
using the regression equations given by Moore et al. (1983).
by the increased 2-hydroxylation of E2 (to inactive
metabolites), which they found in smokers in both the
follicular and the luteal phase. Jensen et al. (1985) found
that smoking reduced the serum concentrations of El and
E2 in postmenopausal women taking ERT: they could not
detect any effect of smoking on endogenous El or E2
concentrations, but these concentrations were at the lower
limit of sensitivity of their assay. They concluded that
smoking increases metabolic clearance of E2. A recent small
study found no differences in serum El and E2 concen-
trations between postmenopausal smokers and non-smokers
(Friedman et al., 1987), but the smokers in this study had
reached menopause more recently than the non-smokers.
Further studies of the effects of smoking on endogenous
oestrogens are required, but it is of interest to examine the
predicted effects of any anti-oestrogenic actions of smoking
in premenopausal and postmenopausal women.
In postmenopausal women, any smoking induced decrease
in E2 will cause a reduction in endometrial mitotic rate and
therefore in the risk of endometrial cancer, because the E2
levels are in the range of 5-20pgml-1, well below the
50pgml-1 upper limit. In premenopausal women, small or
moderate decreases in E2 will have a smaller effect because
even if the early follicular phase E2 drops below the
50pgml upper limit, the progressive rise in E2
concentration during the follicular phase will bring the
concentration above the limit by day 9 or 10, so that
endometrial mitotic activity will only be reduced for a few
days of each cycle. This is consistent with the tentative
conclusion one may draw from the results shown in Table V,
viz. that the effect of smoking in decreasing endometrial
cancer risk is smaller in premenopausal women.
Obesity and risk in premenopausal women
Studies have consistently found that obesity markedly
increases the risk of endometrial cancer in premenopausal
women; the results of the two recent large studies are shown
in Tabe VI. Obesity has not been convincingly associated
with an increase in total E2 concentration in premenopausal
women (Zumoff, 1982), but is certainly associated with a
decrease in SHBG and therefore with an increase in
bioavailable E2. As we discussed above, an increase in
bioavailable E2 is commonly considered to be the cause of
the increased endometrial cancer risk of obese post-
menopausal women. It is clear, however, that increased
bioavailable E2 levels cannot be the cause of the increased
risk in obese premenopausal women, since the plasma
concentration of E2 in premenopausal women is always at or
above the upper limit for effective oestrogen action. This
suggests that the mechanism by which obesity increases risk
in premenopausal women involves progesterone deficiency
rather than E2 excess. This is consistent with evidence that
obesity is associated with amenorrhoea (Rogers & Mitchell,
1952), with subnormal luteal phase progesterone concen-
tration (Sherman & Korenman, 1974), and with irregular
menstrual periods (Hartz et al., 1984; Willett et al., 1985).
The endometrium of a woman with 'normal' ovulatory
cycles proliferates for 14 days in the cycle, i.e. for only some
50% of the time, but the endometrium of a woman with
progesterone deficiency proliferates for more, possibly con-
siderably more, than 50% of the time. Since it is the periods
of proliferation that increase endometrial cancer risk, these
women will be at an increased risk of endometrial cancer, as
is observed.
Hormone replacement therapy
The addition of a progestagen to ERT, a regime commonly
termed hormone replacement therapy (HRT), has been
recommended as a method to prevent the increase in risk of
endometrial cancer which is associated with ERT; 12 to 14
days of progestagen during each 28 days of oestrogen is
considered to be the optimum regime, because clinical study
has shown that this treatment schedule reduces the incidenceUNOPPOSED OESTROGEN HYPOTHESIS AND ENDOMETRIAL CANCER 209
Table V Cigarette smoking and risk ofendometrial cancera
Cases Controls Smoking
Reference N Source N Source Category RRb Comments
Weiss et al. 322 Population, 289 Population, Ever 0.4 No effect ofno.
(1980) 50-74 50-74 ofcigarettes.
Adjusted for weight,
parity and ERT.
Lesko et al. 510 Hospital, 727 Cancer hospital, Current smoker 0.7 Adjusted for
(1985) 30-69 30-69 Current, 25+/d 0.5 weight and ERT.
Pre, 25+/d 0.9
Post, 25+/d 0.5
Tyler et al. 437 Population, 3,200 Population, Ever 0.9 Adjusted for
(1985) 20-54 20-54 Current 0.8 weight, ERT and COC.
Ages -49 1.1
Ages 50+ 0.7
Baron et al. 476 Cancer hospital, 2,128 Cancer hospital, 1-14 pack-years 0.8 Adjusted for marital
(1986) 40-89 women found not 15 + pack-years 0.6 status, Quetelet's
to have cancer, Index and parity.
40-89
Lawrence et al. 200 Hospital, 200 Population, Pre 0.6 Results not altered by
(1987) 40-69 40-69 Post 0.6 controlling for
.1 pack/day 0.7 potential confounders.
>1 pack/day 0.5
Levi et al. 357 Hospital, 1,122 Hospital, Pre 0.5 Results not altered by
(1987) 31-74 25-74 Post 0.4 controlling for
potential confounders.
aAbbreviations: COC =combination-type oral contraceptives; ERT =oestrogen replacement therapy; Post=postmenopausal;
Pre=premenopausal; RR= relative risk; 25+/day=current smoker of 25+ cigarettes per day; bIn all studies controls are age matched or
RRs are adjusted for age.
Table VI Obesity and risk ofendometrial cancer in premenopausal womena
Cases Controls
Weight
Reference N Source N Source kg RRb Comments
Henderson et al. 110 Population 110 Population <59.0 1.0 Adjusted for
(1983) 59.0- 1.5 parity, COC
68.0- 2.0 use.
77.1- 9.6
86.2+ 17.7
LaVecchia et al. 58 Hospital 93 Hospital <52.9c 1.0
(1984) 52.9- 1.5
66.1- 3.9
79.3+ 20.3
aAbbreviations: COC=combination-type oral contraceptive; RR=relative risk; bIn all studies controls are
age matched or RRs are adjusted for age. Henderson et al. (1983) study of age group <46, LaVecchia et al.
(1984) is of premenopausal women; cWeight estimated from Quetelet's Index (kgm-2) using a standard height
of 1.626m.
of endometrial hyperplasia to very low levels (Studd et al.,
1980; Whitehead et al., 1982). The unopposed oestrogen
hypothesis maintains, however, that the crucial variable
which determines the risk of endometrial cancer is the
average mitotic rate (equivalent to the total number of cell
divisions) over the 28 day treatment cycle. Mitotic activity
during 14 days of treatment with oestrogen alone will be
close to the premenopausal follicular phase rate, while
during 14 days of oestrogen and progestagen mitotic activity
will be negligible, mimicking the luteal phase of the
menstrual cycle. This activity has to be compared to the
constant but generally very low mitotic rate in untreated
postmenopausal women. The average endometrial mitotic
rate in women on HRT will thus be considerably greater
than the rate in untreated women (with the possible
exception of extremely obese women, who are rarely given
HRT). We are therefore reasonably certain that HRT will
lead to an increased risk of endometrial cancer. The
increased risk from HRT will not be as great as that
observed with ERT, and no reliable data are yet available on
the magnitude of the risk. [We feel that methodological
shortcomings in the studies of Gambrell (1986) make it
impossible to use his results.] It is, however, possible to
make fairly accurate predictions of the risk by considering
the age-incidence curve of endometrial cancer, and how it
would be modified by HRT (or by other hormonal factors).
The age-incidence curve ofendometrial cancer
The age-incidence curve of endometrial cancer is shown in
Figure 2. Incidence rises rapidly until age 50 (average age at
menopause) and then at a much reduced rate. (To a good
approximation the curve, when plotted on log-log scales, can
be regarded as simply two straight lines joining at210 T.J.A. KEY & M.C. PIKE
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Figure 2 Age-incidence curve for endometrial cancer in the
West Midlands Region 1968-72, and fitted curve from Pike
(1987).
menopause.) The age-incidence curve for breast cancer,
which has a similar shape, has been mathematically analysed
in terms of the multistage theory of carcinogenesis
(Moolgavkar et al., 1980) and Figure 2 could also be
analysed in these terms. Such an analysis leads naturally to
consideration of which stage of carcinogenesis is affected by
various factors and in certain circumstances this is desirable.
The breast cancer age incidence curve has, however, also
been mathematically analysed directly in terms of differing
mitotic rates at differing ages, without the complexity of
defining the stages of carcinogenesis (Pike et al., 1983). We
have adopted this latter approach here since the purpose of
this paper is to examine the effects of various factors on
cancer incidence through their effects on endometrial cell
mitotic rates, rather than to attempt to identify which stage
or stages of carcinogenesis are affected.
Mathematical analysis of Figure 2 shows that it is
completely compatible with the mitotic rate ideas expressed
above (Pike, 1987), and the effects of the various hormonal
factors can be seen most easily by considering their effects
on the age-incidence curve (Figure 3). Although the curves
shown in Figure 3 are calculated from the mathematical
formulae given in Pike (1987), they are best considered as
having been drawn by modifying the average curve (Figure
2) in the obvious ways.
The long-established protective effect of early menopause
is illustrated in Figure 3a, in which menopause at age 50
('normal') is compared with menopause at age 40. The
obvious change here is that the curve for early menopause
has the reduced slope of the postmenopausal period starting
at age 40. The most important point to notice from the
figure is that protection is lifelong.
The mitotic activity of the endometrium in a woman on
HRT roughly mimics the premenopausal period. This is
illustrated in Figure 3b for 5 years of HRT use starting at
menopause (taken as at age 50). Instead of the slope of the
incidence curve decreasing at menopause, it simply continues
to increase at the premenopausal rate for the 5 years of
HRT before changing slope to that normal for the
postmenopausal period. The increased risk from HRT use
will be lifelong. The figure shows that 5 years of such HRT
will increase risk by some 90%, but this is probably an
overestimate because the mitotic rate during the unopposed
oestrogen phase of lower dose HRT (0.625mgday-1 of
CEE) is probably somewhat lower than the rate in the
premenopausal follicular phase. If the peak mitotic rate on
HRT is taken as two-thirds the follicular level (to agree with
the non-SHBG bound E2 level in Table II) then the
estimated 90% increase is reduced to a 50% increase.
The endometrial mitotic activity in a woman on
continuous ERT is nearly equal to that during the follicular
phase of the menstrual cycle, and the total mitotic activity
over a 28-day period is thus roughly double that of a
premenopausal woman. This is illustrated in Figure 3b for 5
years of ERT use starting at menopause (taken as at age 50).
Instead of the slope of the incidence curve decreasing at age
50, or not changing as shown for HRT, the slope will
actually be steeper for the 5 years of ERT. The increased
risk will be lifelong, and the figure predicts that 5 years of
such ERT use will increase risk by some 280%. With the
two-thirds premenopausal rate assumption discussed above
the estimated increase in risk is reduced from 280% to
145%. If the two-thirds assumption is made and ERT is
only given for 21 days with a seven-day break in each treat-
ment cycle, the estimated increase in risk is further reduced
to a 90% increase.
Since endometrial mitotic activity is near zero in women
on COCs, the incidence curve will be very nearly flat during
the time COCs are used. When COCs are stopped the curve
will increase as before, just as if the time on COCs did not
exist. This is illustrated in Figure 3c for 5 years COC use
starting at age 28. The protection against endometrial cancer
is lifelong. The figure shows that five years of COC use will
decrease risk by some 60%.
Finally Figure 3d illustrates the effect of obesity on the
age-incidence curve. In this figure we show the predicted
curve for a woman whose obesity makes her anovular from
age 35. Her endometrial mitotic rate for ages 35 to 50 is
twice the normal premenopausal rate. After menopause her
mitotic rate is equal to the normal premenopausal rate [half
the follicular rate because bioavailable E2 is approximately
half the basal follicular level (see Tables II and IV), but for
double the time (no luteal phase)]. We note that although
the curves continue to separate further after menopause (i.e.
the relative risk continues to increase), a large proportion of
the increased risk in the postmenopausal period is due to the
increased mitotic rate in the premenopausal period.
The magnitudes of the risks illustrated in Figure 3 and
discussed above are close to those observed in epidemio-
logical studies. The long-term effects of menopause are well
known, and long-term benefits of COC use have been
observed in a number of studies [see Centers for Disease
Control (1983)]. The recent large study of ERT use (Shapiro
et al., 1985) also found that the increase in risk persisted for
many years; the apparently contrary findings of some earlier
studies were very probably due to misdiagnoses of
endometrial hyperplasia as cancer (Horwitz and Feinstein,
1986). No adequate studies of HRT have yet been reported.
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